Search

Your search keyword '"van Rijn, Roos S."' showing total 3 results
Start Over Author "van Rijn, Roos S." Database OpenAIRE
3 results on '"van Rijn, Roos S."'

1. Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and quality of life

Abstract

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Published
2022
Full Text
View/download PDF

2. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1):First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., Internal medicine, Obstetrics and gynaecology, AII - Cancer immunology, and CCA - Cancer Treatment and quality of life

Abstract

Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

Published
2021
Full Text
View/download PDF

3. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Radiology & Nuclear Medicine, Internal medicine, Medical oncology, CCA - Cancer Treatment and quality of life, and Obstetrics and gynaecology

Subjects
Male, Survival rate, Cancer Research, Pembrolizumab, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], STAGE-III, Medicine, METASTATIC MELANOMA, Prospective Studies, Registries, Stage (cooking), Melanoma, Netherlands, Aged, 80 and over, education.field_of_study, Middle Aged, Nivolumab, Oncology, Female, Immunotherapy, Adult, medicine.medical_specialty, Population, Antineoplastic Agents, Data management, Disease-Free Survival, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Young Adult, Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, Adjuvants, Immunologic, SDG 3 - Good Health and Well-being, Internal medicine, Humans, education, Aged, Neoplasm Staging, business.industry, IPILIMUMAB, medicine.disease, Skin neoplasms, Discontinuation, Clinical trial, Quality of health care, Neoplasm Recurrence, Local, business
Abstract

Background: Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality and safety of melanoma care in the Netherlands. This study aims to describe treatment patterns, relapse, and toxicity rates of adjuvant-treated melanoma patients beyond the clinical trial setting.Methods: Analyses were performed on adjuvant-treated melanoma patients included in the DMTR. Descriptive statistics were used to analyse patient-, and treatment characteristics. A baseline registration completeness analysis was performed, and an analysis on trial eligibility in clinical practice patients. Recurrence-free survival (RFS) at 12-months was estimated with the Kaplan-Meier method.Results: A total of 641 patients were treated with adjuvant anti-PD-1 therapy. RFS at 12-months was 70.6% (95% CI, 66.9-74.6) with a median follow-up of 12.8 months. Sex, stage of disease and Breslow thickness were associated with a higher hazard for RFS. Eighteen per cent of the anti-PD-1-treated patients developed grade >= 3 toxicity. Sixty-one per cent of patients prematurely discontinued anti-PD-1 therapy.Conclusion: Adjuvant anti-PD-1 treatment of resected stage III/IV melanoma in daily practice showed slightly higher toxicity rates and more frequent premature discontinuation but similar RFS rates compared to trials. (C) 2021 The Authors. Published by Elsevier Ltd.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results